Hanmi Triple Agonist Obesity Drug Begins First Patient Dosing in US Phase 2 Trial
Verification of Weight and Lean Body Mass Improvement Through 36-Week Long-Term Administration
Expansion of Indications to Diabetes Also Underway
Hanmi Pharmaceutical's next-generation triple agonist for obesity treatment, 'HM15275 (LA-GLP/GIP/GCG),' has begun patient dosing after entering Phase 2 clinical trials in the United States.
On February 2, Hanmi Pharmaceutical announced that it had completed dosing the first patient in the Phase 2 clinical trial approximately three months after receiving Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). The Phase 2 trial is expected to be completed in the first half of 2027. The company plans to accelerate development with the goal of commercializing the drug by 2030.
This Phase 2 clinical trial will focus on evaluating weight loss effects and changes in lean body mass in patients with obesity and severe obesity through long-term administration over 36 weeks.
HM15275 is a triple agonist that simultaneously stimulates the glucagon-like peptide (GLP)-1, gastric inhibitory polypeptide (GIP), and glucagon (GCG) receptors. The goal is to achieve greater weight loss compared to existing GLP-1 class drugs while minimizing muscle loss. Hanmi Pharmaceutical is targeting a weight reduction effect of more than 25% of body weight.
Currently available GLP-1-based obesity treatments, such as Wegovy (active ingredient: semaglutide) and Mounjaro (active ingredient: tirzepatide), have demonstrated weight loss effects of about 15?20% in clinical trials. However, they are considered limited because they have not achieved the 25?30% weight loss regarded as comparable to metabolic bariatric surgery.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hanmi Pharmaceutical also plans to expand the indications for HM15275 to include diabetes treatment. In January of this year, the company received FDA approval for a Phase 2 IND to evaluate blood glucose control in diabetic patients and plans to initiate the clinical trial in the first half of this year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.